Real Risks of the Online World

January 28, 2025 updated by: University of Zurich

Real Risks of the Online World: Association of Problematic Online Dating App Use with Mental and Sexual Health Outcomes in Sexual Minorities

Development and validation of questionnaire/scale to assess problematic online dating app (ODA) use in a sub-cohort of the SwissPrEPared cohort study (validation sample: n=229). Longitudinal design to assess the association of problematic ODA use and sexual/mental health and substance use outcomes. No randomised trial, only 1 cohort which will be stratified according to severity/risk of problematic ODA use.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This project may fill an important gap of knowledge in a research area that has taken on major importance over the past few years, and has thus the potential to impact several major public health recommendations. First, considering the high penetrance of dating apps in the men who have sex with men (MSM) population (reaching 78.2% in a recent report), more than 62,000 MSM in Switzerland are estimated to use such applications. How many of them suffer from addiction or problmatic use remains unclear and our project will be the first to provide estimates of the prevalence of problematic ODA use in this particular population. Second, our project will help to clarify the impact of online dating app usage on health outcomes. By identifying drivers of the current HIV/(sexual transmitted infections (STI) epidemic in Switzerland, our project might thus provide critical information to shape future prevention measures aiming at further reducing HIV/STI incidence rates. Third, because sexual risk-taking increases with substance use and depression, it remains crucial to detect mental health outcomes early and provide adequate care to populations at high risk of HIV, or other STI, transmission. Fourth, our study might identify a new phenomenon related to high-risk sexual behaviour that may not be limited to the MSM group, but could also affect other, larger populations interacting and meeting through online communication channels. Considering that more than 41 million people are currently using dating apps in Europe, our findings might have a substantial impact on the general population. Finally, this project might provide the very first insights on the interplay between online dating, substance use, mental health and sexual risk taking. This new understanding could then help Switzerland create additional measures for preventing HIV transmission and reach the UNAIDS targets for HIV elimination by 2030.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
229

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Switzerland
      • Zürich, Switzerland, 8001
        • Epidemiology, Biostatistics and Prevention Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

HIV-negative SwissPrEPared participants (≥ 18 years old) who are active online dating app users.

Description

Inclusion Criteria:

  • currently engaging in online dating (i.e., using applications/websites with the aim to meet potential relationship or sexual partners or having used them actively in the past 12 months)
  • Participating in the SwissPrEPared study at center Checkpoint Zurich
  • German speaking

Exclusion Criteria:

- Potential participants will be excluded if they are unable to follow study procedures.

For Inclusion/Exclusion at the SwissPrEPared study see: NCT03893188 at clinicaltrials.gov

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
HIV-negative SwissPrePared participants who are active Online Dating App (ODA) users
Diagnostic test: to develop and validate a scale measuring problematic online dating app (ODA) use in sexual minorities

Qualitative part: scale development and validation with testing in 3 different participant samples, i.e. preliminary testing (n=10), pilot testing (n=30-60), validation (n=300).

Quantitative part: longitudinal part conducted in the validation sample of the qualitative study part (n=300) with the aim to evaluate the association of scores in the problematic ODA use scale with sexual health and mental health outcomes.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Develop and validate a scale measuring problematic online dating app (ODA) use
Time Frame: single measurement (one day per participant)
Scale development and validation will follow the FDA guidance for patient-reported outcomes and recommendations on questionnaire research. Preliminary testing, pilot-testing, and validation will be conducted in participants from the SwissPrEPared Study
single measurement (one day per participant)
Associated mental, sexual health and substance use outcomes of problematic ODA use
Time Frame: 6 months

Evaluate the association of problematic ODA use with:

Sexual health outcomes (incident cases of STI, such as syphilis, gonorrhoea and chlamydia, or HIV), over 6 months Mental health outcomes: prevalence of psychiatric disorders, measured at baseline and 12 months, using validated questionnaires Substance use outcomes: Lifetime, 12-month, 3-month prevalence and frequency rates
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Zurich

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
University Hospital of Psychiatry Zurich
Center for Forensic Hair Analysis, Zurich

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 23, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 31, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 13, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 15, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 19, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 28, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2020-01545
  • 10001C_192814 (Other Grant/Funding Number: Swiss National Science Foundation)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sexual Health

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings